Company Filing History:
Years Active: 2022-2023
Title: Satyen Gohil: Innovator in Cancer Treatment
Introduction
Satyen Gohil is a prominent inventor based in London, GB. He has made significant contributions to the field of cancer treatment through his innovative research and development of chimeric antigen receptors and antibodies.
Latest Patents
Satyen Gohil holds 3 patents that focus on groundbreaking advancements in cancer therapy. His latest patents include ROR1 CAR T-cells, which describe a chimeric antigen receptor that selectively binds to Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1). This invention highlights the use of T cells comprising the CAR in the treatment of cancer. Another notable patent is for ROR1 antibodies, which specifically bind to a ROR1 polypeptide. These isolated monoclonal antibodies have various applications, including detection, prevention, and treatment of cancer.
Career Highlights
Satyen Gohil is associated with UCL Business Plc, where he continues to push the boundaries of cancer research. His work has garnered attention for its potential to revolutionize treatment options for patients.
Collaborations
He collaborates with esteemed colleagues such as Amit Nathwani and Marco Della Peruta, contributing to a dynamic research environment focused on innovative solutions in healthcare.
Conclusion
Satyen Gohil's contributions to cancer treatment through his patents and collaborations exemplify the impact of innovation in medicine. His work continues to inspire advancements in the field, paving the way for future breakthroughs.